Dear user
I am learning modelling and simulation of the efavirenz compound using
the In Silico PBPK approach. May you please assist with information on
literature where i can obtain input a variety of model input
parameters.
Thank you
Bernard
BernardNgara
Trainee Biostatistician
Africa Institute of Biomedical Science and Technology
P. O Box 2294
Harare
Zimbabwe
+263 772 160 896
efavirenz pbpk input parameters
Dear Bernard,
Here are two references:
Rekić, Dinko, Daniel Röshammar, Jackson Mukonzo, and Michael Ashton. "In silico
prediction of efavirenz and rifampicin drug–drug interaction considering weight
and CYP2B6 phenotype." British journal of clinical pharmacology 71, no. 4
(2011): 536-543.
Siccardi, M., L. Almond, A. Schipani, C. Csajka, C. Marzolini, C. Wyen, N. H.
Brockmeyer, M. Boffito, A. Owen, and D. Back. "Pharmacokinetic and
pharmacodynamic analysis of efavirenz dose reduction using an in vitro–in vivo
extrapolation model." Clinical Pharmacology & Therapeutics 92, no. 4 (2012):
494-502.
Kind regards
Dinko
Quoted reply history
________________________________________
From: [email protected] [[email protected]] on behalf of
Bernard Ngara [[email protected]]
Sent: 01 July 2013 15:52
To: nmusers
Subject: [NMusers] efavirenz pbpk input parameters
Dear user
I am learning modelling and simulation of the efavirenz compound using
the In Silico PBPK approach. May you please assist with information on
literature where i can obtain input a variety of model input
parameters.
Thank you
Bernard
BernardNgara
Trainee Biostatistician
Africa Institute of Biomedical Science and Technology
P. O Box 2294
Harare
Zimbabwe
+263 772 160 896
Hi Bernard
Please see the following two papers and if you search Pubmed you may find
more.
Rekic D, Roshammar D, Mukonzo J, and Ashton M (2011) In silico prediction
of efavirenz and rifampicin drug-drug interaction considering weight and
CYP2B6 phenotype. *Br J Clin Pharmacol* *71:*536-543.
Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, Khoo S, Owen A, and
Back D (2013) Prediction of drug-drug Interactions Between Various
Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a
Physiologically Based Pharmacokinetic Modelling Approach. *Clin
Pharmacokinet* *52:*583-592.
Regards
Masoud
Quoted reply history
On 1 July 2013 14:52, Bernard Ngara <[email protected]> wrote:
> Dear user
>
> I am learning modelling and simulation of the efavirenz compound using
> the In Silico PBPK approach. May you please assist with information on
> literature where i can obtain input a variety of model input
> parameters.
>
> Thank you
>
> Bernard
>
> BernardNgara
> Trainee Biostatistician
> Africa Institute of Biomedical Science and Technology
> P. O Box 2294
> Harare
> Zimbabwe
> +263 772 160 896
>